Status of drug development for the prevention and treatment of osteoporosis (Q38184588)

30 August 2017

title

Status of drug development for the prevention and treatment of osteoporosis (English)

1 reference

30 August 2017

0 references

Peter Schwarz

0 references

Niklas Rye Jørgensen

0 references

Bo Abrahamsen

0 references

language of work or name

English

0 references

publication date

4 February 2014

1 reference

Expert Opinion on Drug Discovery

30 August 2017

published in

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

245-253

1 reference

Bisphosphonates: The first 40years

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Cica-clamp technique: a method for quantifying parathyroid hormone secretion: a sequential citrate and calcium clamp study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Who should receive calcium and vitamin D supplementation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

A pooled analysis of vitamin D dose requirements for fracture prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

A Reverse J-Shaped Association of All-Cause Mortality with Serum 25-Hydroxyvitamin D in General Practice: The CopD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Fracture risk and zoledronic acid therapy in men with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Molecular genetics of too much bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Bone mineral density in sclerosteosis; affected individuals and gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Wnt signaling during fracture repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Latest findings in phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Growth hormone, insulin-like growth factors, and the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

The bisphosphonates: risks and benefits of long term use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Bisphosphonates for postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Safety issues with bisphosphonate therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Genetics of osteoporosis from genome-wide association studies: advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Age- and menopause-related bone loss compromise cortical and trabecular microstructure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.884067

10.1517/17460441.2014.884067

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference